Trials / Unknown
UnknownNCT03228303
Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Assiut University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Nilotinib vs imatinib in patients with newly diagnosed CML-CP
Detailed description
Study size is 100 patients in 2 arms 50 patients in nilotinib ttt 50 patients in imatinib ttt
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nilotinib 150 MG [Tasigna] | Nilotinib vs imatinib in patients with newly diagnosed CML-CP |
| DRUG | Imatinib 400mg | Nilotinib vs imatinib in patients with newly diagnosed CML-CP |
Timeline
- Start date
- 2017-12-01
- Primary completion
- 2020-07-30
- Completion
- 2020-08-01
- First posted
- 2017-07-24
- Last updated
- 2017-10-10
Source: ClinicalTrials.gov record NCT03228303. Inclusion in this directory is not an endorsement.